Dana Levy

Sporos Bioventures Appoints Amit Rakhit, M.D. as Chief Executive Officer

HOUSTON, Texas., September 29, 2021 — Sporos Bioventures, LLC, a private biotechnology company catalyzing the rapid development of breakthrough therapies through a portfolio of companies that target novel disease mechanisms in cancer, fibrosis, inflammation, and immune-related diseases, today announced the appointment of Amit Rakhit, M.D., M.B.A. as chief executive officer. Dr. Rakhit joins Sporos from …

Sporos Bioventures Appoints Amit Rakhit, M.D. as Chief Executive Officer Read More »

Tvardi Therapeutics

Tvardi Therapeutics Raises $74 Million in Series B Financing to Advance Clinical Programs

HOUSTON, Texas, June 23, 2021 — Tvardi Therapeutics, Inc. (“Tvardi”) a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, has closed a $74 million Series B financing. The financing was led by new investors Slate Path Capital, Palkon Capital, ArrowMark Partners, and 683 Capital, with continued support and participation by existing …

Tvardi Therapeutics Raises $74 Million in Series B Financing to Advance Clinical Programs Read More »

Stellanova Therapeutics

Stellanova Therapeutics, Inc. Announces Closing of $15.5 Million Series A Financing

Proceeds will support development of antibody drugs and discovery platform targeting pro-tumorigenic factors produced by fibroblasts in the tumor microenvironment, rendering resistant cancers treatable. Houston, June 3, 2021 – Stellanova Therapeutics, Inc. (“Stellanova”), a biotechnology company advancing cancer therapies targeting the tumor microenvironment, today announced the closing of a $15.5 million Series A financing led by …

Stellanova Therapeutics, Inc. Announces Closing of $15.5 Million Series A Financing Read More »

Asylia Therapeutics News

Asylia Therapeutics, Inc. Announces Closing of $14.5 Million Series A Financing

Proceeds will support development of novel antibody drugs that convert immunologically “cold” tumors into treatable “hot” tumors, with the goal of enhancing effectiveness of cancer immunotherapy.  Houston, May 25, 2021 – Asylia Therapeutics, Inc. (“Asylia”), a development-stage biotechnology company advancing novel immune modulating therapies for cancer and autoimmune diseases, today announced the closing of a $14.5 …

Asylia Therapeutics, Inc. Announces Closing of $14.5 Million Series A Financing Read More »

Sporos Launches with $38.1 Million Series A Financing

Company intends to develop and extend its diverse pipeline of therapies for cancer and immune diseases, beginning with four entities Leadership team includes founding chief financial officer Michael Wyzga, formerly of Genzyme HOUSTON, Texas., May 6, 2021— Sporos Bioventures, LLC (the “Company” or “Sporos”), officially launched today with the close of a $38.1 million Series …

Sporos Launches with $38.1 Million Series A Financing Read More »

Nirogy Therapeutics to Present at AACR Annual Meeting 2021

E-posters highlighting preclinical data demonstrate the potential of Nirogy’s small molecule therapies to enable significant activation of anti-tumor immunity and simultaneous killing of cancer cells in both in vitro and in vivo models Boston, April 7, 2021 – Nirogy Therapeutics Inc., a privately-held biotechnology company developing novel small molecules to target cellular transporters, today announced that …

Nirogy Therapeutics to Present at AACR Annual Meeting 2021 Read More »

Asylia Therapeutics News

JLABS @ TMC and Asylia Therapeutics on Navigating a Powerful Tool: The Human Immune System

Houston: the true third coast of innovation. Texas is home to more than 5,400 life science R&D and manufacturing firms, with more than 106,000 workers employed in related fields (THBI). As one of the top global biotechnology hubs, and home to the largest medical center in the world (Texas Medical Center), it’s no wonder JLABS …

JLABS @ TMC and Asylia Therapeutics on Navigating a Powerful Tool: The Human Immune System Read More »

Nirogy Therapeutics Launches with $16.5 Million Series A Financing

Boston, Massachusetts.  January 26, 2021 – Nirogy Therapeutics Inc., a privately-held biotechnology company developing novel small molecules to target cellular transporters, today announced the closing of a $16.5 million Series A financing. The financing was co-led by Santé Ventures and Sporos. In conjunction with the financing, Dennis McWilliams of Santé and Joseph Kekst of Sporos …

Nirogy Therapeutics Launches with $16.5 Million Series A Financing Read More »

Scroll to Top